Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphodiesterase 4 (PDE4) isoforms are a family of enzymes that specifically hydrolyze cyclic adenosine monophosphate (cAMP), a key second messenger involved in regulating numerous physiological processes. PDE4 isoforms are widely expressed and play essential roles in inflammation regulation, neuroprotection, and metabolism. The PDE4 family consists of four genes: PDE4A, PDE4B, PDE4C, and PDE4D, each producing multiple isoforms with unique N-terminal regions that determine their specific subcellular localization. Different isoforms have distinct regulatory properties, including phosphorylation-dependent modulation and dimerization. PDE4 is a target for anti-inflammatory and immunomodulatory drugs, but current inhibitors lack subtype selectivity, leading to potential side effects.
Inhibition of cAMP hydrolysis, increasing intracellular cAMP levels.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphodiesterase 4 Isoform (PDE4).